The bradykinin-challenge model successfully predicts the efficacious dose range of deucrictibant in bradykinin-mediated angioedema

Background Deucrictibant (PHA-022121) is a novel orally bioavailable bradykinin B2 receptor antagonist under development for prophylaxis and on-demand treatment of bradykinin-mediated angioedema attacks. This study aimed to assess the pharmacological effect of deucrictibant in a bradykinin-challenge model in monkeys, to determine the pharmacologically effective concentration (EC) range in a bradykinin-challenge model in humans, and to inform dose selection for clinical trials of deucrictibant in bradykinin-mediated angioedema. Methods A bradykinin-challenge model was developed in cynomolgus monkeys and applied to healthy participants. In monkeys, effects of deucrictibant on repeated bradykinin-induced transient changes in mean arterial blood pressure (MABP) were evaluated and compared with the effects of icatibant, which was used to pharmacologically validate the model. In humans, the pharmacokinetic/pharmacodynamic (PK/PD) relationship of deucrictibant was established by assessing plasma levels and deucrictibant-mediated inhibition of bradykinin-induced hemodynamic changes. Results Deucrictibant effectively inhibited bradykinin-induced changes in MABP in monkeys with a shorter time to maximal observed effect and a longer duration of effect than icatibant. In humans, single oral doses of deucrictibant (12 and 22 mg) inhibited bradykinin-induced hemodynamic changes from 1 h (first time point measured) onward. PK/PD modeling of human data estimated that plasma concentrations corresponding to the EC 50 of 2.4 ng/mL and EC 85 of 13.8 ng/mL could be maintained for at least 12 h. These parameters provided guidance for the anticipated therapeutic efficacy threshold for deucrictibant in both prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks, informing the selection of dose regimens of deucrictibant for Phase 2 clinical trials. Conclusion Bradykinin-challenge studies in monkeys and humans demonstrated deucrictibant-mediated inhibition of bradykinin-induced hemodynamic changes. The results enabled selection of the Phase 2 dose regimens of deucrictibant that proved to be efficacious in prophylaxis and on-demand clinical trials in bradykinin-mediated angioedema. Clinical trial registration https://clinicaltrials.gov/study/NCT05047185 , identifier NCT05047185; RAPIDe-1: https://clinicaltrials.gov/study/NCT04618211 , identifier NCT04618211.

Authors

Institutions

Publication Details

Journal
Frontiers in Immunology
Published
2026-11-19
DOI
https://doi.org/10.3389/fimmu.2026.1960471
Primary Topic
Coagulation, Bradykinin, Polyphosphates, and Angioedema
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

The bradykinin-challenge model successfully predicts the efficacious dose range of deucrictibant in bradykinin-mediated angioedema

Brigitte Loenders, Peng Lü, Maximilian Georg Posch, Anne Lesage et al.
Frontiers in Immunology
Coagulation, Bradykinin, Polyphosphates, and Angioedema
article

The bradykinin-challenge model successfully predicts the efficacious dose range of deucrictibant in bradykinin-mediated angioedema

Brigitte Loenders, Peng Lü, Maximilian Georg Posch, Anne Lesage, Jochen Knolle, John C. Lukas, Aleena Banerji, Mónica Rodríguez, Marc A. Riedl, Evangelia Pardali, Stephan Schmidt, Markus A.K. Magerl, Christoph Gibson, Kees Groen, Raf Crabbé, Konrad Bork, Juan Bravo, Michiel Joost van Esdonk
article en

Abstract

Background Deucrictibant (PHA-022121) is a novel orally bioavailable bradykinin B2 receptor antagonist under development for prophylaxis and on-demand treatment of bradykinin-mediated angioedema attacks. This study aimed to assess the pharmacological effect of deucrictibant in a bradykinin-challenge model in monkeys, to determine the pharmacologically effective concentration (EC) range in a bradykinin-challenge model in humans, and to inform dose selection for clinical trials of deucrictibant in bradykinin-mediated angioedema. Methods A bradykinin-challenge model was developed in cynomolgus monkeys and applied to healthy participants. In monkeys, effects of deucrictibant on repeated bradykinin-induced transient changes in mean arterial blood pressure (MABP) were evaluated and compared with the effects of icatibant, which was used to pharmacologically validate the model. In humans, the pharmacokinetic/pharmacodynamic (PK/PD) relationship of deucrictibant was established by assessing plasma levels and deucrictibant-mediated inhibition of bradykinin-induced hemodynamic changes. Results Deucrictibant effectively inhibited bradykinin-induced changes in MABP in monkeys with a shorter time to maximal observed effect and a longer duration of effect than icatibant. In humans, single oral doses of deucrictibant (12 and 22 mg) inhibited bradykinin-induced hemodynamic changes from 1 h (first time point measured) onward. PK/PD modeling of human data estimated that plasma concentrations corresponding to the EC 50 of 2.4 ng/mL and EC 85 of 13.8 ng/mL could be maintained for at least 12 h. These parameters provided guidance for the anticipated therapeutic efficacy threshold for deucrictibant in both prophylactic and on-demand treatment of bradykinin-mediated angioedema attacks, informing the selection of dose regimens of deucrictibant for Phase 2 clinical trials. Conclusion Bradykinin-challenge studies in monkeys and humans demonstrated deucrictibant-mediated inhibition of bradykinin-induced hemodynamic changes. The results enabled selection of the Phase 2 dose regimens of deucrictibant that proved to be efficacious in prophylaxis and on-demand clinical trials in bradykinin-mediated angioedema. Clinical trial registration https://clinicaltrials.gov/study/NCT05047185 , identifier NCT05047185; RAPIDe-1: https://clinicaltrials.gov/study/NCT04618211 , identifier NCT04618211.

Frontiers in ImmunologyVol. 17
University of Florida (US), University of California San Diego (US), Humboldt-Universität zu Berlin (DE), Clinical Trial and Consulting (US), Fraunhofer Institute for Translational Medicine and Pharmacology (DE), Hautklinik Heidelberg (DE), Mass General Brigham (US), Freie Universität Berlin (DE), Charité - Universitätsmedizin Berlin (DE)
Coagulation, Bradykinin, Polyphosphates, and Angioedema
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon